Holen Sie sich die Stockscreener-App
2.37
3.95%
0.09
Handel nachbörslich:
2.36
-0.01
-0.42%
Schlusskurs vom Vortag:
$2.28
Offen:
$2.38
24-Stunden-Volumen:
43,069
Relative Volume:
0.04
Marktkapitalisierung:
$4.11M
Einnahmen:
$502.40K
Nettoeinkommen (Verlust:
$-7.91M
KGV:
-0.2377
EPS:
-9.972
Netto-Cashflow:
$-4.32M
1W Leistung:
-15.05%
1M Leistung:
+33.90%
6M Leistung:
-47.46%
1J Leistung:
-81.19%
1-Tages-Spanne:
$2.2201
$2.38
1-Wochen-Bereich:
$2.21
$2.89
52-Wochen-Spanne:
$1.41
$35.99
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Firmenname
60 Degrees Pharmaceuticals Inc
Sektor
Branche
Telefon
202-327-5422
Adresse
1025 CONNECTICUT AVENUE NW, WASHINGTON
Vergleichen Sie SXTP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
2.37 | 4.11M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
60 Degrees Pharmaceuticals Inc Aktie (SXTP) Neueste Nachrichten
60 Degrees Pharmaceuticals Announces 2024 Annual Results - ADVFN
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - ADVFN
60 Degrees Pharmaceuticals (SXTP) Unveils Discrepancies in Babes - GuruFocus
Daily Progress: 60 Degrees Pharmaceuticals Inc (SXTP) Drop -15.51, Closing at 2.67 - DWinneX
60 Degrees Pharmaceuticals Inc (SXTP) Stock: A Comprehensive 52-Week Review - investchronicle.com
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
How is SXTP’s stock performing after recent trades? - uspostnews.com
Shocking Gap: Survey Finds 3 Million Babesiosis Cases While CDC Reports Only 1,834Major Market Opportunity - Stock Titan
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey - Yahoo Finance
Form 8-KCurrent report - ADVFN
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - ADVFN
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Down 43.2% in March - Defense World
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday? - MSN
60 Degrees Pharma's Breakthrough: New Clinical Trials Target Rising Tick-Borne Disease Crisis - Stock Titan
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
60 Degrees and Yale to progress tafenoquin for babesiosis - Yahoo
60 Degrees Pharmaceuticals (SXTP) Reports 2024 Financial Results - GuruFocus
60 Degrees Pharmaceuticals (SXTP) Announces 1-for-5 Reverse Stoc - GuruFocus
60 Degrees Pharma signs patent agreement with Yale for tick disease medicine development - Mugglehead Magazine
60 Degrees Pharmaceuticals signs Patient License Agreement with Yale - TipRanks
TNF Pharmaceuticals Inc: Navigating Market Fluctuations with a 0.75M Market Cap - investchronicle.com
60 Degrees Pharmaceuticals partners with Yale for drug development By Investing.com - Investing.com South Africa
Traders boost bets Fed will start cutting rates in May - Yahoo Finance
Mr. Yoshida's Brings the Heat with New Spicy Wing & Rib Sauce - Yahoo Finance
InventHelp Inventor Develops New Litter Removal Tool for Poultry Houses (JTK-236) - Yahoo Finance
60 Degrees Pharmaceuticals (SXTP) Stock Rallies On Tafenoquine Patent News - Stocks Telegraph
Will Assurant (AIZ) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Donaldson Exhibits Strong Prospects Despite Persisting Headwinds - Yahoo Finance
US trade rep says Trump tariffs are getting results, but things may be 'challenging' for awhile - Yahoo Finance
US Tariff Revenue Gains Seen as Undercut by Declining Trade - Yahoo Finance
SSL or XOM: Which Is the Better Value Stock Right Now? - Yahoo Finance
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - Yahoo Finance
Watch live: U.S. Trade Rep. Jamieson Greer testifying before Senate Finance Committee - Yahoo
60 Degrees Pharmaceuticals (SXTP) Teams with Yale for Tafenoquine Development - GuruFocus
Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March - Benzinga
60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment - marketscreener.com
Sixty Degrees Pharmaceuticals Announces Patent License Agreement To Advance Development Of Tafenoquine - MarketScreener
60 Degrees Pharmaceuticals: Surge or Slump Ahead? - timothysykes.com
SXTP60 degrees pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
60 Degrees Pharmaceuticals partners with Yale for drug development - Investing.com
First-Ever Babesiosis Prevention Drug: Yale Partners with Sixty Degrees on Breakthrough Treatment - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Trump’s Tariff Guru Gives His Personal ‘Guarantee’ There Won’t Be a Recession - Yahoo News
These Bond ETFs Are Still Winning Amid Trump Tariff Selloff - Yahoo Finance
Indian fintech Juspay secures $60m in Series D funding - Yahoo Finance
Laurentian Bank shares an update on the progress of its strategic plan - The Globe and Mail
Finanzdaten der 60 Degrees Pharmaceuticals Inc-Aktie (SXTP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):